--- title: "The Algorithm's Leftovers: From Bankrupt Genomics to New VC Funds in the Market's Edges" type: "News" locale: "en" url: "https://longbridge.com/en/news/296894850.md" description: "What happens to the stocks that don't fit neatly into thematic buckets? From a pioneering biotech filing for Chapter 11 to a hungry tech SPAC, the truth, as usual, is more complicated." datetime: "2026-08-25T10:12:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296894850.md) - [en](https://longbridge.com/en/news/296894850.md) - [zh-HK](https://longbridge.com/zh-HK/news/296894850.md) generator: "portal-rs" --- # The Algorithm's Leftovers: From Bankrupt Genomics to New VC Funds in the Market's Edges I'm told that deep within the automated classification systems of Wall Street, there is always a drawer labeled "Other." These stocks don't end up there because they lack value, but because they are caught at the extreme edges of the corporate lifecycle: they are either just being born, actively dying, or have long been consumed. This matters because when you look at this eclectic group of 10 unclassified equities in 2026, you get a brutally honest snapshot of the market's speculative frontier and its sprawling graveyards. On one end of the spectrum, you have the capital vehicles trying to write new rules. Take **Robinhood Ventures Fund I (RVI.US)**, a growth equity fund that went public in March 2026. It is currently sitting on an ambitious portfolio of private giants, from OpenAI and SpaceX to Stripe. Floating in a similar orbit of unrealized potential is **Artius II Acquisition Inc. Rights (AACBR.US)**. Incorporated back in 2024, this SPAC is still roaming the cross-sections of technology and healthcare, searching for a target that can spin a compelling software or fintech narrative. And yet, capital ambitions do not always guarantee survival, a reality starkly visible in the healthcare space. **Sangamo Therapeutics (SGMOQ.US)**, once a hopeful pioneer in genomic medicines, filed for Chapter 11 bankruptcy in June 2026 and retreated to the OTC markets. By mid-August 2026, the company was forced into a fire sale, offloading its Fabry disease programs and other assets to PTC Therapeutics and Eli Lilly for USD 161 million. Compare that collapse to the ongoing sprint of **BridgeBio Oncology Therapeutics (BBOT.US)**. In August 2026, they showcased highly promising preclinical data for BBO-11818, their KRAS-mutant cancer drug, which already secured an FDA Fast Track designation in April. It is the ultimate winner-take-all dichotomy of biotech. Then you have **Meridian Bioscience (VIVO.US)**, a diagnostics provider that found a different exit entirely—quietly absorbed in a USD 1.53 billion all-cash buyout back in 2022. But there's a catch: the corporate retreat isn't limited to volatile biotechs. Legacy retail and software names are also quietly shuffling off the main stage. In August 2026, Canadian luxury jeweler **Birks Group (BGI.US)** announced its voluntary delisting from the NYSE to trade on the OTCQB venture market, all while navigating the administrative burden of filing its latest supply chain labor reports. Meanwhile, the legacy enterprise collaboration platform **JIVE Software (JIVE.US)** has essentially been a ghost since its USD 462 million acquisition years ago, leaving its ticker in a strange limbo often confused with modern ETFs. With so much displacement, it is no surprise that capital continues to seek absolute safety. This is precisely why the **Kurv Gold Enhanced Income ETF (KGLD.US)** keeps executing its defensive playbook. Throughout the summer of 2026, the fund reliably distributed dividends between USD 0.35 and USD 0.40 per share, offering a yield-focused harbor amidst the chaos. By contrast, massive legacy operators like **United Airlines Holdings (UAL.US)** and the Brazilian arm of **Banco Santander (Brasil) (BSBR.US)** have experienced a remarkably quiet stretch recently, flying under the radar with no major structural shifts or market-rattling headlines to report. My view is that whenever we try to force the market into neat, thematic boxes, we ignore the messy reality of these fringe players. They are the market's unresolved plotlines—either seeds waiting to sprout or carcasses picked clean. Trying to build a cohesive portfolio out of them? Good luck with that. *This article does not constitute investment advice.* ### Related Stocks - [RVI.US](https://longbridge.com/en/quote/RVI.US.md) - [AACBR.US](https://longbridge.com/en/quote/AACBR.US.md) - [JIVE.US](https://longbridge.com/en/quote/JIVE.US.md) - [BGI.US](https://longbridge.com/en/quote/BGI.US.md) - [SGMOQ.US](https://longbridge.com/en/quote/SGMOQ.US.md) - [VIVO.US](https://longbridge.com/en/quote/VIVO.US.md) - [UAL.US](https://longbridge.com/en/quote/UAL.US.md) - [BSBR.US](https://longbridge.com/en/quote/BSBR.US.md) - [BBOT.US](https://longbridge.com/en/quote/BBOT.US.md) ## Related News & Research - [United Airlines is going for global dominance. These are the 10 new international routes it just announced.](https://longbridge.com/en/news/297041202.md) - [United Airlines Adds Service To 10 International Cities](https://longbridge.com/en/news/296907091.md) - [United CEO expects gradual airfare increases in first half of 2027](https://longbridge.com/en/news/296930071.md) - [United Airlines adds 10 international cities for 2027 in largest network expansion](https://longbridge.com/en/news/296902419.md) - [Major Stake Move: Inside a High-Profile Robinhood Ventures Fund I Stock Sale](https://longbridge.com/en/news/296990652.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**